Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-NK-CD19 Cells in Relapsed/Refractory B-cell Malignancies
NCT05410041Phase 1Withdrawn
- Sponsor
- Beijing Boren Hospital
- Start
- May 2022
- Primary completion
- Jul 2025
- Modality
- Gene Editing, Gene Silencing, Lymphokine-Activated Killer Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD19 CAR NK cells in acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL), sponsored by Beijing Boren Hospital. Primary endpoints: Safety of CAR NK-CD19 Cell at 3 months and Overall Response Rate at 3 months. Planned start May 2022; status: withdrawn.
02
Drugs
CD19 CAR NK cells
03
Conditions
acute lymphoblastic leukemia (ALL)chronic lymphocytic leukemia (CLL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT05410041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05410041.